Product category:
Proteomics
News Release from: Activotec | Subject: Activo-P11 peptide synthesiser
Edited by the Laboratorytalk Editorial
Team on 11 April 2007
Peptide synthesiser stars at German
symposium
Activotec selected the recent 8th German Peptide Symposium in Heidelberg, Germany, to display its latest products and proprietary techniques for peptide synthesis
Covering topics including peptides in cancer research and therapy, glycopeptides, peptide chemistry, pharmaceutical peptide manufacture and peptide / protein synthesis and engineering the symposium drew a large audience of researchers, about 40% of these coming from countries other than Germany Chris Littlewood, CEO of Activotec commented: " Traffic to our exhibition stand was constant throughout the show
This article was originally published on Laboratorytalk on 20 Sep 2006 at 8.00am (UK)
Related stories
Innovations in peptide synthesis attract visitors
Marking its global debut at EPS - the Activo-P11 Peptide Synthesiser is an easy to use and affordable instrument for synthesis of very high quality peptides
Easy to use instrument for peptide synthesis
Activotec has announced the Activo-P11 peptide synthesiser - an easy to use and affordable instrument for synthesis of very high quality peptides
"We were particularly pleased with the strong interest shown in our Activo-P11 peptide synthesiser and in our proprietary techniques in peptide backbone modification used to develop modified GLP-1 analogues".
The Activo-P11 peptide synthesiser is described as an easy to use and affordable instrument for synthesis of very high quality peptides.
Designed and manufactured in Europe the fully automated and enclosed system performs a wide range of chemistries to synthesise peptides of any length in the 0.1-1.0mmol scale.
Combined with very easy-to-use software, designed by chemists for chemists, the Activo-P11 was one of the most visited attractions at the exhibition.
Particular interest was also shown in a technical poster describing a study in which it Activotec had applied its proprietary technologies in peptide backbone modification to develop a set of modified GLP-1 analogues which have been stabilised against proteolysis, yet are at least as active as native GLP-1 in both promoting insulin release in cell assays and lowering blood glucose in small animal models.
These exciting results drew considerable attention from biotech and pharmaceutical industry researchers involved in the diabetes therapeutic area.
Activotec, which has its trading base in Cambridge (UK) and an R+D and production facility in Southampton (UK), was founded in 2002 as a spin out from the internationally renowned School of Biological Sciences at the University of Southampton.
Activotec is a customer-focused company providing high technology products and services for chemistry and biochemistry applications.
Activotec provides a complete range of products and services for peptide and protein synthesis.
• Activotec: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
